CA2227421A1 - Utilisation d'ipriflavone pour reduire le nombre de lymphocytes cd8+ - Google Patents
Utilisation d'ipriflavone pour reduire le nombre de lymphocytes cd8+ Download PDFInfo
- Publication number
- CA2227421A1 CA2227421A1 CA002227421A CA2227421A CA2227421A1 CA 2227421 A1 CA2227421 A1 CA 2227421A1 CA 002227421 A CA002227421 A CA 002227421A CA 2227421 A CA2227421 A CA 2227421A CA 2227421 A1 CA2227421 A1 CA 2227421A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- decrease
- isopropoxyisoflavone
- ipriflavone
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
La présente invention concerne une composition pharmaceutique appropriée pour diminuer le nombre de cellules CD8+ comprenant comme principe actif de la 7-isopropoxyisoflavone en mélange avec des transporteurs inertes appropriés, solides ou liquides, et, facultativement, des additifs et adjuvants thérapeutiques usuels. La composition pharmaceutique de l'invention est préparée par des méthodes connues et convient pour le traitement des sujets humains ou animaux dont l'état rend souhaitable la suppression sélective des lymphocytes CD8+.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HUP9502198 | 1995-07-21 | ||
HU9502198A HU9502198D0 (en) | 1995-07-21 | 1995-07-21 | Novel indication |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2227421A1 true CA2227421A1 (fr) | 1997-02-06 |
Family
ID=10987063
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002227421A Abandoned CA2227421A1 (fr) | 1995-07-21 | 1996-07-16 | Utilisation d'ipriflavone pour reduire le nombre de lymphocytes cd8+ |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP0841915A1 (fr) |
JP (1) | JP2001503371A (fr) |
KR (1) | KR19990028933A (fr) |
CN (1) | CN1191483A (fr) |
AR (1) | AR002905A1 (fr) |
AU (1) | AU6367096A (fr) |
BG (1) | BG102182A (fr) |
BR (1) | BR9610187A (fr) |
CA (1) | CA2227421A1 (fr) |
CZ (1) | CZ2798A3 (fr) |
EA (1) | EA199800146A1 (fr) |
EE (1) | EE9800020A (fr) |
HR (1) | HRP960345A2 (fr) |
HU (1) | HU9502198D0 (fr) |
IL (1) | IL122751A0 (fr) |
MX (1) | MX9800603A (fr) |
NO (1) | NO980127D0 (fr) |
PL (1) | PL324460A1 (fr) |
SK (1) | SK3298A3 (fr) |
WO (1) | WO1997003664A1 (fr) |
YU (1) | YU42796A (fr) |
ZA (1) | ZA966079B (fr) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1241079B (it) * | 1990-03-23 | 1993-12-29 | Chiesi Farma Spa | Composizioni farmaceutiche contenenti ipriflavone,procedimento per la loro preparazione e relativo impiego terapeutico |
HU212932B (en) * | 1993-08-02 | 1996-12-30 | Chinoin Gyogyszer Es Vegyeszet | Parmaceutical composition containing ipriflavone, hydroxyapatit and tricalciumphosphate for treating lack of bones and process for producing the composition |
-
1995
- 1995-07-21 HU HU9502198A patent/HU9502198D0/hu unknown
-
1996
- 1996-07-16 EA EA199800146A patent/EA199800146A1/ru unknown
- 1996-07-16 CN CN96195722A patent/CN1191483A/zh active Pending
- 1996-07-16 IL IL12275196A patent/IL122751A0/xx unknown
- 1996-07-16 CZ CZ9827A patent/CZ2798A3/cs unknown
- 1996-07-16 KR KR1019980700235A patent/KR19990028933A/ko not_active Application Discontinuation
- 1996-07-16 CA CA002227421A patent/CA2227421A1/fr not_active Abandoned
- 1996-07-16 MX MX9800603A patent/MX9800603A/es unknown
- 1996-07-16 JP JP50646497A patent/JP2001503371A/ja active Pending
- 1996-07-16 PL PL96324460A patent/PL324460A1/xx unknown
- 1996-07-16 EE EE9800020A patent/EE9800020A/xx unknown
- 1996-07-16 AU AU63670/96A patent/AU6367096A/en not_active Abandoned
- 1996-07-16 BR BR9610187A patent/BR9610187A/pt not_active Application Discontinuation
- 1996-07-16 EP EP96923004A patent/EP0841915A1/fr not_active Withdrawn
- 1996-07-16 WO PCT/HU1996/000038 patent/WO1997003664A1/fr not_active Application Discontinuation
- 1996-07-16 SK SK32-98A patent/SK3298A3/sk unknown
- 1996-07-17 ZA ZA9606079A patent/ZA966079B/xx unknown
- 1996-07-18 HR HRP9502198A patent/HRP960345A2/hr not_active Application Discontinuation
- 1996-07-19 YU YU42796A patent/YU42796A/sh unknown
- 1996-07-22 AR ARP960103677A patent/AR002905A1/es unknown
-
1998
- 1998-01-12 NO NO980127A patent/NO980127D0/no unknown
- 1998-01-14 BG BG102182A patent/BG102182A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
AR002905A1 (es) | 1998-04-29 |
EE9800020A (et) | 1998-08-17 |
SK3298A3 (en) | 1998-07-08 |
KR19990028933A (ko) | 1999-04-15 |
AU6367096A (en) | 1997-02-18 |
EP0841915A1 (fr) | 1998-05-20 |
CZ2798A3 (cs) | 1998-06-17 |
MX9800603A (es) | 1998-04-30 |
BG102182A (en) | 1998-08-31 |
IL122751A0 (en) | 1998-08-16 |
NO980127L (no) | 1998-01-12 |
JP2001503371A (ja) | 2001-03-13 |
HU9502198D0 (en) | 1995-09-28 |
PL324460A1 (en) | 1998-05-25 |
ZA966079B (en) | 1998-01-19 |
EA199800146A1 (ru) | 1998-08-27 |
BR9610187A (pt) | 1998-07-28 |
YU42796A (sh) | 1999-03-04 |
WO1997003664A1 (fr) | 1997-02-06 |
NO980127D0 (no) | 1998-01-12 |
HRP960345A2 (en) | 1998-02-28 |
CN1191483A (zh) | 1998-08-26 |
WO1997003664A8 (fr) | 1999-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69837324T2 (de) | Behandlung der multiplen sklerose durch einnahme von copolymer-1 | |
US20050049205A1 (en) | Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents | |
Dutra et al. | Euphol prevents experimental autoimmune encephalomyelitis in mice: evidence for the underlying mechanisms | |
US10660865B2 (en) | Cannabidiol for the prevention and treatment of graft-versus-host disease | |
Ichikawa et al. | The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers | |
WO2009102021A1 (fr) | Traitement de maladie rétinienne par activation de la fonction de cellule souche issue de moelle osseuse ou de cellule progénitrice de celle-ci | |
JP2003510353A (ja) | 自己免疫疾患、慢性ウイルス性および細胞内細菌性感染症の治療のためのアスタキサンチン等のキサントフイルの使用 | |
EP0251134A2 (fr) | Compositions pour prévenir le rejet de la greffe | |
WO2015114315A1 (fr) | Utilisation de cladribine pour traiter la neuromyélite optique | |
Pabst et al. | Regeneration of heterotopically transplanted autologous splenic tissue | |
WO2004103263A2 (fr) | Dopamine et ses agonistes et antagonistes permettant de traiter des maladies neurodegeneratives | |
AU615745B2 (en) | Method of effecting immunosuppression | |
Hawley et al. | Association between ICAM-1 expression and metastatic capacity of murine B-cell hybridomas | |
CA2227421A1 (fr) | Utilisation d'ipriflavone pour reduire le nombre de lymphocytes cd8+ | |
Ryffel et al. | Immunosuppressive effect of cyclosporin A in two lymphocyte transfer models in rats: comparison of in vivo and in vitro treatment | |
KR102316961B1 (ko) | 면역억제제로서의 벤젠 유도체의 면역억제용 약학적 조성물 | |
EP0680756B1 (fr) | Utilisation d'une combinaison d'antinéoplastones pour la fabrication d'un médicament pour le traitement de la neurofibromatose | |
KR102383866B1 (ko) | 자가 면역 질병 및 당뇨병의 치료를 위한 바이러스 벡터 및 그의 제조방법 및 응용 | |
Tomioka et al. | In vivo antileprosy activity of the newly synthesized benzoxazinorifamycin, KRM-1648 | |
CN110882240A (zh) | 作为急性缺血性中风的治疗剂的多酚衍生物化合物6-cepn | |
EP4292663A2 (fr) | Utilisation de cladribine pour le traitement d'une maladie neuromusculaire auto-immune | |
MXPA98000603A (en) | Use of ipriflavona to reduce the number of cells c | |
Strober | ‘Managing’the Immune System With Total Lymphoid Irradiation | |
US11944601B2 (en) | Applications of ellagic acid in preparation of immunomodulatory medicines for treatment of neuromyelitis optica or immune rejection after skin transplantation | |
JP2928608B2 (ja) | インスリン依存型糖尿病予防または治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |